Barinthus Biotherapeutics (NASDAQ:BRNS) Posts Earnings Results, Beats Estimates By $0.02 EPS

Barinthus Biotherapeutics (NASDAQ:BRNS) posted its quarterly earnings data on Thursday. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02, FiscalAI reports.

Barinthus Biotherapeutics Trading Up 6.0%

BRNS traded up $0.03 on Friday, hitting $0.60. 34,881 shares of the stock traded hands, compared to its average volume of 40,767. The business has a fifty day moving average price of $0.64 and a two-hundred day moving average price of $0.64. The firm has a market capitalization of $24.47 million, a PE ratio of -0.58 and a beta of -0.39. Barinthus Biotherapeutics has a 52 week low of $0.51 and a 52 week high of $1.83.

Institutional Trading of Barinthus Biotherapeutics

A hedge fund recently raised its position in Barinthus Biotherapeutics stock. Renaissance Technologies LLC increased its position in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 115.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 143,100 shares of the company’s stock after purchasing an additional 76,800 shares during the quarter. Renaissance Technologies LLC owned approximately 0.35% of Barinthus Biotherapeutics worth $100,000 at the end of the most recent quarter. 25.20% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $4.00.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.